Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03817970 · ClinicalTrials.gov registry record · Phase 3
Cisplatin Disposition and Kidney Injury
A Phase 3 study of Nephrotoxicity, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT03817970 is a Phase 3 study of Nephrotoxicity that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 72 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03817970, a Phase 3 study of Nephrotoxicity, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidney injury due to cisplatin therapy.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Granisetron
- DRUG Palonosetron
Study Locations (2)
Colorado
- UCHealth-Metro Denver - Denver
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-11-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03817970
The ClinicalTrials.gov registry entry for NCT03817970 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nephrotoxicity appearing as the primary indexed condition, and to 3 interventions - of which Ondansetron is the first listed.
NCT03817970 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, New York.
Frequently Asked Questions
What is clinical trial NCT03817970 about?
NCT03817970 is a clinical study titled "Cisplatin Disposition and Kidney Injury". This study is being done to determine 1) whether drugs to treat cisplatin-related nausea can influence harm to the kidneys, 2) whether cisplatin levels in the body can influence the risk of harm to the kidneys, and 3) whether a person's genetic make-up can increase or decrease the likelihood of kidn...
What is the current status of trial NCT03817970?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2019-11-15. Estimated completion is 2027-12-31.
What conditions does trial NCT03817970 study?
This clinical trial studies the following conditions: Nephrotoxicity.
What interventions are being tested in trial NCT03817970?
The interventions under investigation include: Ondansetron (DRUG), Granisetron (DRUG), Palonosetron (DRUG).
Who is sponsoring clinical trial NCT03817970?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03817970 being conducted?
This trial has 2 study locations across Colorado, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrotoxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.